These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18324875)

  • 1. The safety of dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Ceravolo R
    Expert Opin Drug Saf; 2008 Mar; 7(2):111-27. PubMed ID: 18324875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU; Lewitt PA; Fernandez HH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson's disease: is the initial treatment established?
    Ahlskog JE
    Curr Neurol Neurosci Rep; 2003 Jul; 3(4):289-95. PubMed ID: 12930698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease.
    Cerri S; Blandini F
    Expert Opin Pharmacother; 2020 Dec; 21(18):2279-2291. PubMed ID: 32804544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor agonists in the therapy of Parkinson's disease.
    Foley P; Gerlach M; Double KL; Riederer P
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1375-446. PubMed ID: 15480844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term studies of dopamine agonists.
    Hubble JP
    Neurology; 2002 Feb; 58(4 Suppl 1):S42-50. PubMed ID: 11909984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
    Zhang J; Tan LC
    Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.